(Q39566677)

13 September 2017

1 reference

title

Anti-oestrogens in the treatment of breast and gynaecological cancers (English)

1 reference

13 September 2017

Furr BJ

1

1 reference

13 September 2017

publication date

1 September 1988

1 reference

Bailliere's clinical obstetrics and gynaecology

13 September 2017

published in

1 reference

13 September 2017

volume

2

1 reference

13 September 2017

issue

3

1 reference

13 September 2017

page(s)

567-580

1 reference

Tamoxifen as primary treatment of breast cancer in elderly or frail patients: a practical management

13 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2888%2980044-0

7 January 2021

Reversible ocular toxicity related to tamoxifen therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2888%2980044-0

7 January 2021

Effects of tamoxifen on blood coagulation

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2888%2980044-0

7 January 2021

A study of estrogen and progesterone cytosol receptor concentration in benign and malignant ovarian tumors and a review of malignant ovarian tumors treated with medroxy-progesterone acetate

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2888%2980044-0

7 January 2021

Modulation of natural killer cell activity by tamoxifen in stage I post-menopausal breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2888%2980044-0

7 January 2021

A comparison of two doses of tamoxifen (Nolvadex) in postmenopausal women with advanced breast cancer: 10 mg bd versus 20 mg bd.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2888%2980044-0

7 January 2021

A randomized comparison of tamoxifen with surgical oophorectomy in premenopausal patients with advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2888%2980044-0

7 January 2021

Tamoxifen and arterial thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2888%2980044-0

7 January 2021

Epidemiology and prevention: workshop report

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2888%2980044-0

7 January 2021

Tamoxifen treatment of metastatic breast cancer and antithrombin III levels

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2888%2980044-0

7 January 2021

Adjuvant chemotherapy with and without tamoxifen in the treatment of primary breast cancer: 5-year results from the National Surgical Adjuvant Breast and Bowel Project Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2888%2980044-0

7 January 2021

The pharmacology and clinical uses of tamoxifen

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2888%2980044-0

7 January 2021

Prospective randomised trial of tamoxifen versus surgery in elderly patients with breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2888%2980044-0

7 January 2021

The effect of tamoxifen on bone mineral content in premenopausal women with breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2888%2980044-0

7 January 2021

Tamoxifen retinopathy at low dosage

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2888%2980044-0

7 January 2021

Treatment of early localized breast cancer in elderly patients by Tamoxifen

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2888%2980044-0

7 January 2021

Randomized trial of bilateral oophorectomy versus tamoxifen in premenopausal women with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2888%2980044-0

7 January 2021

Chemoendocrine therapy vs chemotherapy alone for advanced breast cancer in postmenopausal women: Preliminary report of a randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2888%2980044-0

7 January 2021

Evidence that tamoxifen is a histamine antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2888%2980044-0

7 January 2021

Tamoxifen is a calmodulin antagonist in the activation of cAMP phosphodiesterase

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2888%2980044-0

7 January 2021

Calcium antagonism by the antioestrogen tamoxifen

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2888%2980044-0

7 January 2021

Antioestrogens in the management of hormone-dependent cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2888%2980044-0

7 January 2021

Tamoxifen and thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2888%2980044-0

7 January 2021

Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer. 'Nolvadex' Adjuvant Trial Organisation

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2888%2980044-0

7 January 2021

Tamoxifen as initial sole treatment of localised breast cancer in elderly women: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2888%2980044-0

7 January 2021

Tamoxifen and medroxyprogesterone therapy for advanced endometrial carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2888%2980044-0

7 January 2021

The Christie Hospital tamoxifen (Nolvadex) adjuvant trial for operable breast carcinoma--7-yr results

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2888%2980044-0

7 January 2021

The Stockholm trial on adjuvant tamoxifen in early breast cancer. Correlation between estrogen receptor level and treatment effect

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2888%2980044-0

7 January 2021

Long-term tamoxifen adjuvant therapy in node-positive breast cancer: a metabolic and pilot clinical study

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2888%2980044-0

7 January 2021

Chemotherapy versus chemotherapy plus hormonotherapy in postmenopausal advanced breast cancer patients a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2888%2980044-0

7 January 2021

Retinopathy caused by treatment with tamoxifen in low dosage

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2888%2980044-0

7 January 2021

Steroidal pure antioestrogens

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2888%2980044-0

7 January 2021

The value of high dose tamoxifen in postmenopausal breast cancer patients progressing on standard doses: A pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2888%2980044-0

7 January 2021

The use of an LH-RH agonist (ICI 118630, Zoladex) in advanced premenopausal breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2888%2980044-0

7 January 2021

10.1016/S0950-3552(88)80044-0

Identifiers

DOI

1 reference

13 September 2017

1 reference